These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28761324)

  • 1.
    Nakai S; Honda S; Matsumiya W; Miki A; Nakamura M
    Mol Vis; 2017; 23():514-519. PubMed ID: 28761324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Miki A; Honda S; Nakamura M
    Jpn J Ophthalmol; 2019 Sep; 63(5):389-395. PubMed ID: 31376050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Bessho H; Honda S; Kondo N; Negi A
    Mol Vis; 2011 Apr; 17():977-82. PubMed ID: 21541271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
    Valverde-Megías A; Veganzones-de-Castro S; Donate-López J; Maestro-de-Las-Casas ML; Megías-Fresno A; García-Feijoo J
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2091-2098. PubMed ID: 28744656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of LOC387715/ARMS2 (rs10490924) Gene Polymorphism with Age-Related Macular Degeneration in the Brazilian Population.
    Hirata FE; de Vasconcellos JP; Medina FM; Rim PH; Fulco EA; de Melo MB
    Ophthalmic Genet; 2015; 36(3):224-8. PubMed ID: 24372405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration.
    Weingessel B; Mihaltz K; Vécsei-Marlovits PV
    Wien Klin Wochenschr; 2016 Aug; 128(15-16):560-5. PubMed ID: 25787216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study.
    Akagi-Kurashige Y; Tsujikawa A; Yuzawa M; Ishibashi T; Nakanishi H; Nakatani E; Teramukai S; Fukushima M; Yoshimura N;
    Jpn J Ophthalmol; 2018 Mar; 62(2):137-143. PubMed ID: 29224056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters.
    Veritti D; Lanzetta P
    Ophthalmologica; 2013; 230(3):131-7. PubMed ID: 23948986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
    Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
    Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
    Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
    Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of methylenetetrahydrofolate reductase C677T polymorphism on the efficacy of photodynamic therapy in patients with neovascular age-related macular degeneration.
    Parmeggiani F; Gallenga CE; Costagliola C; Semeraro F; Romano MR; Dell'Omo R; Russo A; De Nadai K; Gemmati D; D'Angelo S; Bolletta E; Sorrentino FS
    Sci Rep; 2019 Feb; 9(1):2614. PubMed ID: 30796269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
    Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration.
    Feng X; Xiao J; Longville B; Tan AX; Wu XN; Cooper MN; McAllister IL; Isaacs T; Palmer LJ; Constable IJ
    Ophthalmology; 2009 Oct; 116(10):1908-12.e1. PubMed ID: 19692124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadruple therapy leads to a sustained improvement of vision in patients with wet age-related macular degeneration.
    Koss MJ; Lewicka-Chomont A; Schramm K; Rejdak R; Ohrloff C; Koch FH
    Ophthalmologica; 2011; 226(2):45-50. PubMed ID: 21546780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited macular translocation compared with photodynamic therapy in the management of subfoveal choroidal neovascularization in age-related macular degeneration.
    Pawlak D; Glacet-Bernard A; Papp M; Roquet W; Coscas G; Soubrane G
    Am J Ophthalmol; 2004 May; 137(5):880-7. PubMed ID: 15126153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined photodynamic therapy and intravitreal injection of triamcinolone acetonide in patients with wet form of AMD. Introductory report].
    Mozolewska-Piotrowska K; Krzystolik K; Karczewicz D; Drobek-Słowik M; Kubasik-Kładna K
    Klin Oczna; 2011; 113(7-9):233-6. PubMed ID: 22256564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the APOE gene and the location of retinal fluid in eyes with neovascular age-related macular degeneration.
    Wickremasinghe SS; Sandhu SS; Amirul-Islam FM; Abedi F; Richardson AJ; Baird PN; Guymer RH
    Retina; 2014 Dec; 34(12):2367-75. PubMed ID: 25077528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.